Nanobiotix S.A. (EPA:NANO)
France · Delayed Price · Currency is EUR 15.76
-2.14 (-11.96%)
Nov 3, 2025, 5:35 PM CET
Nanobiotix Revenue
Nanobiotix had revenue of 26.64M EUR in the half year ending June 30, 2025, with 708.93% growth. This brings the company's revenue in the last twelve months to 10.16M, down -75.93% year-over-year. In the year 2024, Nanobiotix had annual revenue of -7.19M, down -119.86%.
Revenue (ttm)
10.16M
Revenue Growth
-75.93%
P/S Ratio
74.80
Revenue / Employee
98.63K
Employees
108
Market Cap
759.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | -7.19M | -43.40M | -119.86% |
| Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
| Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
| Dec 31, 2021 | 2.65M | 322.00K | 13.85% |
| Dec 31, 2020 | 2.33M | -216.00K | -8.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
| Sartorius Stedim Biotech | 2.95B |
Nanobiotix News
- 3 days ago - Nanobiotix (NBTX) Secures $71M Financing Deal with HealthCare Royalty - GuruFocus
- 4 days ago - NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth - GlobeNewsWire
- 4 weeks ago - Nanobiotix (NBTX) Sees Stock Rise on Promising Cancer Drug Trial Results - GuruFocus
- 4 weeks ago - Nanobiotix gains after early-stage trial data for J&J-partnered cancer drug - Seeking Alpha
- 4 weeks ago - Top 2 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
- 4 weeks ago - NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer - GlobeNewsWire
- 4 weeks ago - Nanobiotix S.A. GAAP EPS of -€0.11, revenue of €26.6M - Seeking Alpha
- 4 weeks ago - NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results - GlobeNewsWire